Since some of them also lead to substantial weight loss, specific GLP-1 receptor agonists (GLP-1 RA), such as liraglutide 3 mg, are now also approved in some countries for the treatment of obesity in non-diabetic patients[136]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.